Рет қаралды 2,074
In this episode of Downsized, hosts Laraine and Christopher Durham discuss recent news in the weight loss and GLP-1 medication world, including Eli Lilly's $5.3 billion investment in Mounjaro and Zepbound, and Novo Nordisk's response to Senator Bernie Sanders' complaints about drug pricing. The episode also features personal updates on their weight loss journeys, including their experiences with different GLP-1 medications and their recent trip to Amsterdam. They highlight their weekly weigh-in totals and discuss how they manage their weight loss while traveling. Additionally, they address how GLP-1 medications affect taste sensitivity, referencing new research presented recently. The hosts encourage viewers to like, subscribe, and share their weight loss stories.
DOWNSIZED GLP-1 COMPANION PRODUCT STORE: thedownsized.org/downsized-st...
DOWNSIZED WEBSITE: thedownsized.org/
Start your weight loss journey today! We use Mochi Health: joinmochi.com/. Use Laraine’s code for $40 off: QIYGO8.
00:00 Introduction and Weekly Updates
01:09 Weight Loss Journey Details
02:50 Travel Experiences and Challenges
06:19 Amsterdam Adventures
10:39 Food and Dining in Amsterdam
13:54 Biking in Amsterdam
15:07 Amsterdam Bike Ride Experience
17:21 Returning Home and Graduation Preparations
18:04 Graduation Day and Family Celebrations
19:39 Post-Graduation Brunch and Reflections
21:16 Eli Lilly's Major Investment in Weight Loss Drugs
27:03 Novo Nordisk's Response to Pricing Complaints
30:53 Ozempic's Surprising Effects on Taste
34:41 Closing Remarks and Future Plans